HUT47217A - Process for producing pharmaceutical compositions containing indol derivatives as active components - Google Patents

Process for producing pharmaceutical compositions containing indol derivatives as active components

Info

Publication number
HUT47217A
HUT47217A HU882611A HU261188A HUT47217A HU T47217 A HUT47217 A HU T47217A HU 882611 A HU882611 A HU 882611A HU 261188 A HU261188 A HU 261188A HU T47217 A HUT47217 A HU T47217A
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
active components
producing pharmaceutical
indol derivatives
Prior art date
Application number
HU882611A
Other languages
English (en)
Other versions
HU201871B (en
Inventor
David A Owen
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT47217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of HUT47217A publication Critical patent/HUT47217A/hu
Publication of HU201871B publication Critical patent/HU201871B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
HU882611A 1987-05-21 1988-05-20 Process for producing pharmaceutical compositions containing indole derivatives as active components HU201871B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712073A GB8712073D0 (en) 1987-05-21 1987-05-21 Medicament

Publications (2)

Publication Number Publication Date
HUT47217A true HUT47217A (en) 1989-02-28
HU201871B HU201871B (en) 1991-01-28

Family

ID=10617727

Family Applications (1)

Application Number Title Priority Date Filing Date
HU882611A HU201871B (en) 1987-05-21 1988-05-20 Process for producing pharmaceutical compositions containing indole derivatives as active components

Country Status (21)

Country Link
US (2) US4824860A (hu)
EP (1) EP0299602B1 (hu)
JP (1) JPH062672B2 (hu)
AT (1) ATE83659T1 (hu)
AU (1) AU599792B2 (hu)
CA (1) CA1305421C (hu)
DE (1) DE3876877T2 (hu)
DK (1) DK169609B1 (hu)
ES (1) ES2052717T3 (hu)
GB (1) GB8712073D0 (hu)
GR (1) GR3007251T3 (hu)
HK (1) HK1000913A1 (hu)
HU (1) HU201871B (hu)
IE (1) IE63511B1 (hu)
LU (1) LU90098I2 (hu)
MX (1) MX9203543A (hu)
NL (1) NL970006I2 (hu)
NZ (1) NZ224709A (hu)
PH (1) PH23867A (hu)
PT (1) PT87542B (hu)
ZA (1) ZA883602B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) * 1996-06-19 1996-08-21 Smithkline Beecham Plc Novel treatment
ES2179362T3 (es) * 1996-08-27 2003-01-16 Wyeth Corp Derivados de 4-aminoetoxi indolona.
CA2327477A1 (en) * 1998-04-13 1999-10-21 James Albert Nelson 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
DE60313005T2 (de) * 2002-09-13 2007-12-20 Motac Neuroscience Ltd. Behandlung von dyskinesie mit 2,3-benzodiazepinen
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20090325911A1 (en) * 2005-10-21 2009-12-31 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of Androgens for the Treatment of Parkinson's Disease
CA2648479C (en) * 2006-04-06 2014-10-28 Nupathe Inc. Implants for the treatment of dopamine associated states
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
US20110195117A1 (en) * 2008-09-01 2011-08-11 Lupin Limited Controlled release compositions of ropinirole
US20110262537A1 (en) 2008-09-29 2011-10-27 Premchand Nakhat Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2563347B1 (en) 2010-04-30 2016-10-12 Teikoku Pharma USA, Inc. Propynylaminoindan transdermal compositions
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
SG11201502681WA (en) 2012-11-02 2015-05-28 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
WO2015168616A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones

Also Published As

Publication number Publication date
HK1000913A1 (en) 1998-05-08
DK275488A (da) 1988-11-22
EP0299602B1 (en) 1992-12-23
HU201871B (en) 1991-01-28
PT87542A (pt) 1989-05-31
ZA883602B (en) 1989-04-26
NL970006I1 (nl) 1997-04-01
ATE83659T1 (de) 1993-01-15
NL970006I2 (nl) 1997-10-01
NZ224709A (en) 1997-02-24
GB8712073D0 (en) 1987-06-24
JPS63303966A (ja) 1988-12-12
GR3007251T3 (hu) 1993-07-30
ES2052717T3 (es) 1994-07-16
US4912126A (en) 1990-03-27
DK169609B1 (da) 1994-12-27
EP0299602A3 (en) 1990-06-06
JPH062672B2 (ja) 1994-01-12
PH23867A (en) 1989-11-23
IE881469L (en) 1988-11-21
US4824860A (en) 1989-04-25
IE63511B1 (en) 1995-05-03
AU599792B2 (en) 1990-07-26
PT87542B (pt) 1992-09-30
DE3876877T2 (de) 1993-04-29
MX9203543A (es) 1992-07-01
EP0299602A2 (en) 1989-01-18
AU1644588A (en) 1988-11-24
DE3876877D1 (de) 1993-02-04
LU90098I2 (fr) 1997-09-25
DK275488D0 (da) 1988-05-19
CA1305421C (en) 1992-07-21

Similar Documents

Publication Publication Date Title
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
HUT43843A (en) Process for production of derivatives of benzimidasole and medical compounds containing thereof
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
EP0285008A3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
IL85945A0 (en) Pharmaceutical compositions containing 2'-fluoronucleosides and derivatives thereof,certain such novel compounds and their preparation
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
HUT46224A (en) Process for producing pharmaceutical compositions containing prostaglandin e1-derivatives
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
IL60217A (en) 4'-deoxyparomomycin derivatives,process for their preparation and pharmaceutical compositions containing them
ES8705463A1 (es) Un procedimiento para la preparacion de 1-metil-4,5-dihi- droorotil-histidil-prolinamida
ZA891769B (en) Heterocyclic compounds
GB8608893D0 (en) D-nor-7-ergoline derivatives
HUT57227A (en) 2'-dezamino-4'-desoxy-4'-amino-8-fluoro-anthracycline derivatives, process for producing them as well as pharmaceutical preparatives containing said compounds as active substance
MX9601424A (es) Indenoilguanidinas sustituidas antiarritmicas y cardioprotectoras.
EP0207514A3 (en) 1,4-dihydropyridine derivatives, process for preparing them, pharmaceutical composition and use